Trump's budget proposal promises to 'fix injustice of high drug prices'

12 March 2019

US President Donald Trump has made slashing drug prices a priority in his fiscal year 2020 budget.

Mr Trump’s budget is taking “bold steps to increase access and reduce drug costs for Americans,” the proposal document states, and it quotes the President’s own words when he said in January: “One of my greatest priorities is to reduce the price of prescription drugs.

"Prices will come down"“In many other countries, these drugs cost far less than what we pay in the USA. That is why I have directed my administration to make fixing the injustice of high drug prices one of our top priorities. Prices will come down.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK